CombiGene
2,66
SEK
+9,02 %
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
+9,02%
0%
0%
-18,9%
-1,12%
+2,11%
-77,76%
-88,01%
-97,23%
combigene.com
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Omsætning
5,54 mio.
EBIT %
-696,75 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
COMBI
Daglig lav / høj pris
2,38 / 2,68
SEK
Markedsværdi
52,67 mio. SEK
Aktieomsætning
39,49 t SEK
Volumen
15 t
Finanskalender
Ekstraordinær generalforsamling
10.12.2024
Årsrapport
14.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Orpahazyme AS | 10,0 % | 10,0 % |
Jan Ivar Nordqvist | 9,5 % | 9,5 % |
Avanza Pension | 6,5 % | 6,5 % |
M&L Industriförvaltning AB | 3,3 % | 3,3 % |
Thoren Tillväxt AB | 2,5 % | 2,5 % |
Nordnet Pensionsförsäkring AB | 2,3 % | 2,3 % |
Ferstad, Arne | 1,5 % | 1,5 % |
Thomassen Skaar, Christian | 1,3 % | 1,3 % |
Molse, Oliver | 1,3 % | 1,3 % |
Olsson, Per Magnus | 1,3 % | 1,3 % |
ViserAlle indholdstyper
CombiGene conducts Extraordinary General Meeting
Shareholders’ proposal for election of Board of Directors
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools